Over nearly 3 decades, organs from donors with hepatitis C virus (HCV) have been widely used for recipients with HCV without detrimental impact on recurrence, graft survival, or the incidence of cholestatic hepatitis. The recent availability of highly effective antiviral therapy has dramatically decreased the number of HCV-viremic transplant candidates, contributing to underutilization of HCV-viremic donors in recent years. Combined with an increase in HCV-viremic donors due to opioid overdose death, experts have proposed the use of HCV-viremic donors in HCV-negative transplant recipients with post-transplant DAA therapy.

中文翻译：

---

HCV-Viremic 器官用于 HCV 阴性接受者：实践是否超越了证据？

近 30 年来，来自丙型肝炎病毒 (HCV) 供体的器官已被广泛用于 HCV 受体，而不会对复发、移植物存活或胆汁淤积性肝炎的发生率产生不利影响。最近获得高效抗病毒疗法已大大减少了 HCV 病毒血症移植候选者的数量，导致近年来 HCV 病毒血症供体的利用率不足。结合因阿片类药物过量死亡导致 HCV 病毒血症捐献者的增加，专家建议在移植后 DAA 治疗的 HCV 阴性移植受者中使用 HCV 病毒血症捐献者。